Denali Therapeutics (NASDAQ:DNLI) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a report published on Wednesday,Zacks reports. The firm issued a strong-buy rating on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($1.61) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.53) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($1.51) EPS and FY2030 earnings at ($0.14) EPS.

DNLI has been the topic of a number of other reports. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. UBS Group increased their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Morgan Stanley increased their target price on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday. B. Riley Financial lifted their target price on shares of Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Finally, BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Denali Therapeutics in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $36.15.

Denali Therapeutics Stock Performance

NASDAQ DNLI traded up $0.35 on Wednesday, hitting $20.07. 1,586,647 shares of the stock traded hands, compared to its average volume of 1,699,561. The business’s fifty day moving average is $20.16 and its two-hundred day moving average is $21.27. Denali Therapeutics has a 12 month low of $13.75 and a 12 month high of $27.30. The firm has a market capitalization of $3.21 billion, a price-to-earnings ratio of -11.60 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million during the quarter, compared to the consensus estimate of $12.67 million. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. As a group, equities analysts anticipate that Denali Therapeutics will post -2.28 EPS for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,857 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the sale, the insider directly owned 281,763 shares in the company, valued at approximately $7,063,798.41. The trade was a 1.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc grew its holdings in Denali Therapeutics by 13.0% during the 3rd quarter. Aberdeen Group plc now owns 1,520,605 shares of the company’s stock valued at $31,431,000 after buying an additional 175,124 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Denali Therapeutics by 1.9% in the third quarter. Fisher Asset Management LLC now owns 2,460,545 shares of the company’s stock valued at $50,859,000 after acquiring an additional 46,383 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Denali Therapeutics by 19.5% in the third quarter. Russell Investments Group Ltd. now owns 102,813 shares of the company’s stock valued at $2,125,000 after acquiring an additional 16,781 shares during the period. Pier 88 Investment Partners LLC boosted its position in shares of Denali Therapeutics by 27.6% in the third quarter. Pier 88 Investment Partners LLC now owns 16,200 shares of the company’s stock valued at $335,000 after acquiring an additional 3,500 shares during the period. Finally, Alps Advisors Inc. grew its stake in Denali Therapeutics by 32.0% during the third quarter. Alps Advisors Inc. now owns 211,772 shares of the company’s stock valued at $4,377,000 after acquiring an additional 51,394 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s third-quarter results beat expectations: EPS was $0.37 versus the consensus estimate of a $0.27 loss, and revenue was $17.78 million versus a $12.67 million estimate. Denali Therapeutics earnings beat and valuation article
• Positive Sentiment: Commercial momentum and potential catalysts may be lifting sentiment: a report cited nearly fivefold growth in Avlayah sales, broader reimbursement coverage, and multiple upcoming pipeline catalysts. Shares were reported up 7.8% after the earnings release. Zacks report on Denali post-earnings performance
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong Buy” rating, providing a new bullish analyst view. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s forecasts show losses continuing in coming years, though its estimates narrow to a $0.14-per-share loss by 2030. The longer-term outlook is therefore still dependent on commercial growth and pipeline progress.
• Neutral Sentiment: A separate report put Denali’s valuation back in focus after the earnings-driven move, suggesting investors may weigh the improved results against the stock’s valuation. Denali earnings and valuation article

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.